生技製藥研發計畫之實質選擇權評價

Real Option Valuation of Biopharmaceutical R&D project

洪育凱(Yu-Kai Hung)

指導教授 ： 李存修

國立臺灣大學/管理學院/財務金融學研究所/碩士(2009年)

https://doi.org/10.6342/NTU.2009.10029

摘要

生技製藥產業不同於傳統產業，其研發投入成本龐大且開發時程長，加上研發過程中的高失敗率，使獲利具高度不確定性；然而，經理人可藉由決策的調整適時放棄或出售投資計畫，提高計畫價值。傳統評價方法(如淨現值法)無法反應計畫過程中的決策彈性，有鑑於此，本論文採用複合實質選擇權評價概念(compound real option)，建立二元樹模型，將生技製藥階段性研發的特質、放棄及出售的選擇權納入考量，希望有助於未來生技製藥公司進行資本預算評估、計畫授權時的評價。

關鍵字

生技製藥 ； 複合實質選擇權 ； 二元樹

並列摘要

Biopharmaceutical industry has been regarded as a highly risky business because of the characteristics such as high capital investment, long developing time, and low success rates. During the developing process, however, managers have the flexibility to adjust the investment project. For example, the R&D project can be abandoned or sold to other companies. The managerial flexibilities can contribute to the project value. Traditional valuation methods are unable to fully capture the value created by the biopharmaceutical R&D project because they ignore these opportunities. Therefore, we apply the compound real option concept and present the binomial lattice model with options to abandon and sell, so as to evaluate the R&D project value.

並列關鍵字

biopharmaceutical ； compound real option ； binomial tree

參考文獻

Beuzekom, B. van and A. Arundel, 2006, OECD biotechnology

statistics – 2006.

The valuation of a NDA using a 6-fold compound option, Research

Cox, J.C., S.A. Ross, and M. Rubinstein, 1979, Option pricing: a simplified approach, Journal of Financial Economics 7, 229-263.

drug discovery and development, Nature Reviews 3, 417-429.